ArriVent BioPharma (AVBP) Projected to Post Earnings on Monday

ArriVent BioPharma (NASDAQ:AVBP) is anticipated to announce its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect the company to announce earnings of ($0.87) per share for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, March 5, 2026 at 9:30 AM ET.

ArriVent BioPharma Stock Down 1.1%

Shares of AVBP stock opened at $22.97 on Friday. The firm has a 50 day moving average price of $21.95 and a two-hundred day moving average price of $20.74. ArriVent BioPharma has a 12-month low of $15.47 and a 12-month high of $26.00. The company has a market capitalization of $948.20 million, a PE ratio of -5.42 and a beta of 1.02.

Wall Street Analysts Forecast Growth

AVBP has been the subject of several recent analyst reports. Truist Financial began coverage on ArriVent BioPharma in a research note on Tuesday, November 25th. They set a “buy” rating and a $43.00 target price for the company. Cantor Fitzgerald initiated coverage on ArriVent BioPharma in a report on Monday, December 22nd. They set an “overweight” rating on the stock. BTIG Research assumed coverage on shares of ArriVent BioPharma in a research report on Wednesday, December 10th. They set a “buy” rating and a $45.00 price objective for the company. Zacks Research upgraded shares of ArriVent BioPharma from a “strong sell” rating to a “hold” rating in a research report on Friday, December 5th. Finally, Citigroup reduced their price target on shares of ArriVent BioPharma from $33.00 to $31.00 and set a “buy” rating for the company in a report on Tuesday, November 11th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, ArriVent BioPharma presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.00.

Institutional Trading of ArriVent BioPharma

Hedge funds and other institutional investors have recently bought and sold shares of the business. Infinitum Asset Management LLC raised its holdings in ArriVent BioPharma by 6.6% during the fourth quarter. Infinitum Asset Management LLC now owns 4,123,923 shares of the company’s stock worth $82,973,000 after buying an additional 255,000 shares during the last quarter. Suvretta Capital Management LLC increased its position in shares of ArriVent BioPharma by 10.9% during the fourth quarter. Suvretta Capital Management LLC now owns 4,106,035 shares of the company’s stock worth $82,613,000 after acquiring an additional 402,583 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of ArriVent BioPharma by 36.8% in the 3rd quarter. Vanguard Group Inc. now owns 2,029,531 shares of the company’s stock worth $37,445,000 after acquiring an additional 545,991 shares during the last quarter. State Street Corp raised its holdings in shares of ArriVent BioPharma by 6.3% in the 4th quarter. State Street Corp now owns 1,091,980 shares of the company’s stock worth $21,971,000 after acquiring an additional 64,352 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in ArriVent BioPharma by 5.2% in the 4th quarter. Geode Capital Management LLC now owns 753,519 shares of the company’s stock valued at $15,164,000 after acquiring an additional 37,231 shares in the last quarter. Institutional investors own 9.48% of the company’s stock.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.